Therefore, it can be inferred that the fusion of anti-CD19 scFv to TCRγδ could mimic the in vitro cytotoxicity of anti-PD-L1 scFv by targeting and killing tumor cells in an antigen-specific manner. The gene discussed is CD19; the disease is neoplasm.